SAB Biotherapeutics (SABS) reports 150,000-share director stock option grant

Rhea-AI Filing Summary

SAB Biotherapeutics, Inc. disclosed that a director received a new stock option grant as part of 2025 board compensation. On December 16, 2025, the director was granted a stock option to purchase 150,000 shares of common stock at an exercise price of $3.99 per share, expiring on December 16, 2035. The filing shows the director beneficially owning 150,000 derivative securities directly after this transaction.

According to the disclosure, this grant represents the director’s 2025 annual grant for board service. The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027. The award was made under the company’s 2021 Omnibus Equity Incentive Plan, as amended, which governs how equity-based compensation is issued to eligible participants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lucera Erick

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)(2)	$3.99	12/16/2025		A		150,000		(1)	12/16/2035	Common Stock	150,000	$0	150,000	D

Explanation of Responses:

1. Represents the 2025 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

2. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

	/s/ Erick Lucera	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SAB Biotherapeutics (SABS) report in this Form 4?

The company reported that a director received a stock option grant on December 16, 2025 as part of 2025 board compensation.

How many SAB Biotherapeutics (SABS) shares are covered by the new stock option?

The new stock option covers 150,000 shares of SAB Biotherapeutics common stock.

What is the exercise price and expiration date of the SAB Biotherapeutics (SABS) director option grant?

The option has an exercise price of $3.99 per share and expires on December 16, 2035.

When do the SAB Biotherapeutics (SABS) director stock options vest?

The shares underlying the option vest in two equal annual installments on December 16, 2026 and December 16, 2027.

Under which plan was the SAB Biotherapeutics (SABS) option grant made?

The award was made under the company’s 2021 Omnibus Equity Incentive Plan, as amended.

What is the reporting person’s relationship to SAB Biotherapeutics (SABS)?

The reporting person is identified as a Director of SAB Biotherapeutics, Inc.